Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis

NCT: NCT07191860 · RECRUITING

NCT IDNCT07191860
StatusRECRUITING
Start Date2026-02-24
Completion2030-11-01
SponsorAiriver Medical, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The OXYGEN-RCT trial is a randomized, controlled, double blinded, prospective, multi-center trial to demonstrate the safety and efficacy in adult benign central airway stenosis. Participates will be in a 1:1 allocation to treatment with the Airiver Pulmonary DCB or standard of care laryngoscopic/bronchoscopic balloon dilation, respectively.

Frequently Asked Questions

What is Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis?

Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis is a clinical trial registered under NCT07191860. Current status: RECRUITING.

What is the status of NCT07191860?

The current status of NCT07191860 (Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis) is: RECRUITING.

When did Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis start?

Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis started on 2026-02-24.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.